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DObjective: The MiCardia DYANA annuloplasty system (MiCardia Corp, Irvine, Calif) is a nitinol-based dy-
namic complete ring that allows modification of the septal-lateral diameter under transesophageal echocardiog-
raphy guidance in the loaded beating heart after mitral valve repair. Shape alteration is induced by
radiofrequency via detachable activation wires. This multicenter study reports the first human experience
with this device.
Methods: Patients (n¼ 35, 67 8 years) with degenerative (n¼ 29), functional/ischemic (n¼ 5), or rheumatic
(n¼ 1) mitral regurgitation underwent mitral valve repair using the new device. We analyzed the occurrence of
death, endocarditis, ring dehiscence, systolic anterior motion, thromboembolism, pulmonary edema, heart
block, ventricular arrhythmia, hemolysis, or myocardial infarction at 30 days (primary end point) and 6 months
(secondary end point) postprocedure.
Results: All patients exhibited mitral regurgitation of 2 or less early postoperatively and at 6 months follow-up.
In 29 patients, the initial mitral valve repair result was satisfactory and no ring activation was required. In 6 pa-
tients, the nitinol-based ring was deformed intraoperatively postrepair with further improvement of mitral regur-
gitation in all cases (preactivation: 0.9 0.2, postactivation: 0.2 0.3; P¼ .001). One death (2.9%, multisystem
organ failure, non–device related), 2 ventricular arrhythmias (5.7%), and 1 heart block (2.9%) occurred, all in
the first 30 days after surgery. No additional major adverse clinical events occurred later than 1 month postpro-
cedure (total observed major adverse clinical event rate 11.5%).
Conclusions: The implantation of the new dynamic annuloplasty ring allows for safe mitral valve repair. The
option of postrepair modification of the septal-lateral diameter by radiofrequency may further optimize repair
results. (J Thorac Cardiovasc Surg 2013;145:425-9)Mitral valve (MV) repair has become recognized as the
procedure of choice for mitral regurgitation (MR) of any
cause,1-3 including those with cardiomyopathy and
functional MR.4 Standard MV repair usually includes
the implantation of an annuloplasty ring,2-5 because
remodeling of the mitral annulus by ring annuloplasty
improves the durability of the repair.6 One of the major
determinants of recurrent MR post-MV repair is the pres-
ence of residual MR in the operating room.6 Thus, the sur-
geon should aim for a near perfect repair with trivial or no
MR at the end of the procedure. Residual MR 2þ or
greater should not be tolerated and may require further re-
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The Journal of Thoracic and Cacrossclamping. The risk of recurrent MR may need to
be weighed against the risk of prolonged ischemic time
and postoperative myocardial dysfunction, particularly in
patients with preoperative impaired left ventricular
function.
Residual or recurrent MR occurs in 30% of patients after
undersized ring annuloplasty for functional MR.7-9
Experimental studies have emphasized that reduction of
the septal-lateral diameter reduces functional MR.10,11
Thus, further reduction of the septal-lateral diameter may
be desirable if residual MR is observed on postrepair trans-
esophageal echocardiography (TEE).
Systolic anterior motion (SAM) of the anterior mitral
leaflet may complicate repair of degenerative MR. If stan-
dard treatment with volume loading, avoidance of ino-
tropes, and beta-blockade fails, implantation of a larger
ring may be required. Thus, increase of the septal-lateral di-
ameter may be desirable to eliminate this life-threatening
complication in some patients.
With the use of an adjustable annuloplasty ring, an imper-
fect MV repair may be optimized by altering the
septal-lateral diameter in the loaded beating heart under
echocardiographic guidance. The objective of this study
was to assess the safety and efficacy of a new deformable
nickel-titanium (Nitinol)-based annuloplasty ring (DYANA
Dynamic Annuloplasty Ring System; MiCardia Corp, Ir-
vine, Calif) in a prospective, multicenter trial.rdiovascular Surgery c Volume 145, Number 2 425
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
DYANA ¼ Dynamic Annuloplasty System with
Activation for the Treatment of Mitral
Regurgitation
MACE ¼ major adverse clinical event
MR ¼ mitral regurgitation
MV ¼ mitral valve
NYHA ¼ New York Heart Association
SAM ¼ systolic anterior motion
TEE ¼ transesophageal echocardiography
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The Dynamic Annuloplasty System with Activation for the Treatment
of Mitral Regurgitation (DYANA) study was designed as a multicenter,
nonrandomized, single-arm clinical trial and conducted in accordance
with the Declaration of Helsinki, with Good Clinical Practice guidelines,
local regulations, and ISO 14155 specifications. Clinical data were ob-
tained on 35 patients treated with the MiCardia Dynamic Annuloplasty
Ring System in 5 surgical centers (Homburg n ¼ 7, Leipzig n ¼ 11, Stutt-
gart n¼ 8, Kiel n¼ 4, Royal Oak n¼ 5). The study was approved by local
ethics committees in each surgical center. Informed consent was obtained
from each patient before undergoing any procedure or preoperative evalu-
ation specific to this protocol.
Evaluation included transthoracic or transesophageal echocardio-
graphic assessment of MR and heart rhythm before implantation, at the
time of implantation, at hospital discharge, at 30 days, and at 6 months
postprocedure. MR was quantified using the ratio of regurgitant jet area/
left atrial area, vena contracta, or proximal isovelocity surface area by
a core echo laboratory. In addition, a complete blood count, brain natri-
uretic peptide, lactate dehydrogenase, hematocrit, and creatinine were
measured preoperatively and 6 months postimplantation. The anticoagula-
tion regimen was according to local practice at each investigational site.Device
The MiCardia DYANA annuloplasty device (MiCardia enCor Mitral
Valve Repair System) is a rigid complete ring available in sizes 28 to 36
mm (Figures 1 and 2). Without radiofrequency activation, it functions as
a standard complete annuloplasty ring. The nitinol support is
encapsulated in silicone and covered with a polyester cloth to allow for
suture attachment and to promote tissue ingrowth and healing. The
device is otherwise constructed with commercially available
annuloplasty ring materials and has been tested for biocompatibility. By
using radiofrequency energy, the nitinol support can be heated to effect
a change in shape allowing shortening (D device) or lengthening (Dþ
device) of the septal-lateral distance by 0.5 to 3.0 mm and the intercommis-
sural distance by 1.0 to 3.5 mm (Figure 3). The shape alteration during ring
activation is a non-reversible, unidirectional process. Intraoperative activa-
tion wires were used for delivery of energy to the annuloplasty ring for ac-
tivation purposes. The distal ends of the wires were attached to the
annuloplasty ring, and the proximal ends were attached to a radiofrequency
generator. After surgical implantation of the annuloplasty ring, the proxi-
mal ends of the activation wires were passed through the atriotomy, the
left atrium was closed, and the patient was weaned from cardiopulmonary
bypass (CPB). If TEE examination revealed residual MR, the surgeon
could apply the radiofrequency current to activate the ring. The activation
wires were disengaged and removed through the atriotomy suture line at
the end of the procedure in all patients before closure of the sternum.426 The Journal of Thoracic and Cardiovascular SurgStudy End Points
Primary and secondary safety end points were defined as the occurrence
of death, endocarditis, ring dehiscence, SAM, thromboembolism, pulmo-
nary edema, heart block, arrhythmia, hemolysis, or myocardial infarction
at 30 days and 6 months postprocedure.
The primary efficacy end point was defined as the ability to reduce MR
to less than 2þimmediately after surgical implantation of the annuloplasty
device. The secondary efficacy end point was defined as the ability to fur-
ther reduce residual MR after intraoperative activation of the device.
RESULTS
Patient Data
Thirty-five patients received the study device between
December 2008 and September 2009. Mean age was 67 
8 years, the majority of patients were male (22/35 or
62.9%), mean height was 171  9 cm, and average weight
was 77 15 kg. Eleven patients (31.4%) were in New York
Heart Association (NYHA) class II functional class, 23 pa-
tients (65.7%) were in NYHA class III, and 1 patient
(2.9%) was in NYHA class IV. Cause of MR was degener-
ative in 29 patients, functional in 5 patients, and rheumatic
in 1 patient. Pulmonary hypertension was present in 9 of 35
patients, and atrial fibrillation was present in 15 of 35 pa-
tients. Relevant comorbidities were hypertension (22/35),
coronary artery disease (9/35), previous myocardial infarc-
tion (3/35), cardiomyopathy (4/35), hyperlipidemia (12/
35), chronic obstructive pulmonary disease (4/35), and dia-
betes (3/35).
Operative Data
Surgery was performed with standard techniques using
median sternotomy and standard CPB cannulation in 18
of 35 patients and minimally invasive techniques via a right
mini-thoracotomy in 17 of 35 patients. Mean CPB time was
132 44 minutes, and myocardial ischemic time was 82 
32 minutes. Median ring size was 32 mm (range, 28–36
mm). Thirty implanted annuloplasty ring systems were of
type D, and 5 implanted devices were of type Dþ. Concom-
itant procedures consisted of tricuspid valve repair (n ¼ 9),
atrial ablation (n ¼ 15), coronary artery bypass grafting
(n ¼ 7), aortic valve replacement (n ¼ 2), aortic valve re-
pair, and ascending aortic replacement (n ¼ 1). The opera-
tion was a redo procedure in 1 patient who previously
underwent coronary artery bypass grafting.
Safety End Points
One patient died 2 days after surgery. The primary cause
of death was multisystem organ failure and was considered
noncardiac and non–device related. In total, 1 death (2.9%),
2 ventricular arrhythmias (5.7%), and 1 heart block (2.9%)
occurred, all within the first 30 days following device im-
plantation. No additional major adverse clinical events
(MACE) occurred later than 1 month postprocedure. There-
fore, the total observed MACE rate was 11.5% (4 events in
35 patients).ery c February 2013
FIGURE 1. Schematic of the dynamic annuloplasty device.
FIGURE 3. Schematic of the 2 subtypes of the dynamic annuloplasty de-
vice: The Dshaped device has been designed for patients with functional
MR and allows reduction of the septal-lateral dimension in the loaded beat-
ing heart postrepair if residual MR is encountered. The Dþshaped device is
intended for patients with degenerative MR and allows increase of the
septal-lateral dimension if SAM is encountered postrepair.
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Residual MR was detected intraoperatively during the
postrepair TEE in 6 patients. Decrease of the septal-
lateral diameter (D in all 6 cases) in the beating heart
post-CPB (Table 1) improved MR in all 6 patients (preacti-
vation: 0.9  0.2, postactivation: 0.2  0.3; P ¼ .001 by
paired t test). None of the patients receiving Dþdevices re-
quired activation for treatment of SAM.
At postprocedural investigation, all patients exhibited
MR less than 2þ. Six months after surgery, 16 patients
(47.1%) had no MR, 7 patients (20.6%) had trace MR, 7
patients (20.6%) had MR grade 1þ, and 3 patients had
MR grade 2þ (8.8%). All 3 patients with MR grade 2þ
had MR grade 3þ before surgery. Detailed MR data at all
study time points are provided in Table 2.
DISCUSSION
The primary objective of this study was to evaluate the
safety and efficacy of a new dynamic, radiofrequency-
activated annuloplasty device in a patient population under-
going MV repair with or without concomitant procedures.
One of the cornerstones of MV repair is the implantation
of an annuloplasty ring device. Ring implantation improvesFIGURE 2. Schematic of the dynamic annuloplasty device.
The Journal of Thoracic and Caleaflet coaptation by reducing annular area, and subse-
quently results in less residual MR in the perioperative
phase.1 The use of an annuloplasty ring also minimizes fu-
ture recurrent MR by decreasing forces on the leaflets and
subvalvular apparatus during systole, as well as by prevent-
ing future annular dilatation. Several ring devices have been
developed, and their results have been extensively re-
ported.12-17 Ring design may be partial or complete;
flexible, semi-flexible, or rigid; or disease-specific
(eg, IMR-ETLogix, Myxo-ETlogix, Edwards Lifesciences,
Irvine, Calif).18,19 However, none of these annuloplasty
rings allow major intrinsic shape changes during or
postimplantation.
MV repair for functional MR due to ischemic or dilative
cardiomyopathy continues to be a challenge for cardiac sur-
geons. Residual or recurrent MR is observed in up to 30%
of patients.7-9,20 Standard treatment for functional MR
includes undersized ring annuloplasty. Annular dilatation
is seen in all patients with functional MR, and
experimental studies have demonstrated that septal-lateral
cinching eliminates functional MR.10,11 Some patientsTABLE 1. Intraoperative data from 6 patients who underwent
activation of a Dshaped dynamic annuloplasty device
Patient
no. Disease
BSA
(m2)
ring
(mm)
MR
before
MR
after
MR
activity
1 FMR 2.18 34 3 1 0
2 DMR 1.51 34 4 1 0.5
3 FMR 2.13 34 2 0.5 0
4 FMR 1.72 32 4 1 0*
5 DMR 2.02 30 3 1 0
6 DMR 1.95 30 3 1 0
FMR, Functional mitral regurgitation; DMR, degenerative mitral regurgitation; MR,
mitral regurgitation; BSA, body surface area. *Papillary muscle repositioning with
a STRING technique23 already reduced MR from 1 to 0.5.
rdiovascular Surgery c Volume 145, Number 2 427
TABLE 2. Summary of mitral regurgitation grade by time interval
Time point MR grade N %
1. Preprocedural 2 3 9
3 23 66
4 9 26
2. Postprocedural 0 26 74
0–1 8 23
1 1 3
3. Discharge 0 26 77
0–1 4 12
1 2 6
Missing 2 6
4. Follow-up 30 d 0 13 38
0–1 8 24
1 3 9
2 2 6
Missing 8 24
5. Follow-up 6 mo 0 16 47
0–1 7 21
1 7 21
2 3 9
Missing 1 3
MR, Mitral regurgitation.
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displacement. Adjunctive repair techniques, such as cutting
of second order chordae,21 leaflet extension,22 or papillary
muscle repositioning,23 have been proposed to relieve leaf-
let tethering. Most surgeons, however, continue to rely on
implantation of an undersized complete ring device. This
concept of aggressive undersizing for functional MR is
based on the Bolling concept4 and includes downsizing by
at least 2 sizes in relation to the intertrigonal distance. Re-
cent studies have demonstrated that aggressive downsizing
may lead to functional mitral stenosis with decreased func-
tional capacity and elevated pulmonary artery pres-
sures.24,25 Accordingly, aggressive undersizing has been
regarded by some as patient prosthesis-mismatch for MV
repair. Concerns regarding induced mitral stenosis, com-
bined with the relatively high incidence of observed MR re-
currence, have led some cardiac surgeons to search for other
alternatives to the undersized annuloplasty operation. The
use of a dynamic annuloplasty ring could be an appealing
alternative for patients with functional MR. The surgeon
could initially choose a mild to moderately undersized
ring with a greater annular area. If residual MR is encoun-
tered during intraoperative TEE, the septal-lateral distance
can be tailored postrepair under TEE guidance in the loaded
beating heart.
MV repair for degenerative disease also involves the in-
sertion of a ring annuloplasty device in the majority of pa-
tients. The ring device is usually sized according to the size
of the anterior leaflet. A typical complication of MV repair
surgery for degenerative disease is SAM of the anterior mi-
tral leaflet, leading to left ventricular outflow tract428 The Journal of Thoracic and Cardiovascular Surgobstruction. This potentially life-threatening complication
occurs in approximately 10% to 15% of patients after
MV repair26,27 and may be precipitated by the use of
complete undersized rings, excessive leaflet tissue
(Barlow’s disease) with inadequate height of the posterior
mitral leaflet, hypovolemia, and excessive inotropic
support. Alternative ring design in the Edwards Myxo-
ETlogix ring with increased septal-lateral diameter intends
to avoid SAM in patients with myxomatous valves.19 The
option of increasing septal-lateral distance postrepair in
case of SAM by using a dynamic ring (Dþ) may thus be
an appealing alternative.
The DYANA annuloplasty device is a complete rigid ring
available in sizes 28 to 36 mm. The new device uses
a nickel-titanium (Nitinol) metallic support for rigidity
and shaping. If postrepair TEE reveals residual MR, the re-
pair can be improved through a modification of septal-
lateral diameter using radiofrequency activation. Indeed,
we observed a significant reduction in MR grade in the 6 pa-
tients who required ring activation postrepair (from 0.9 
0.2 to 0.2  0.3, P ¼ .001). Follow-up echocardiography
also revealed good results with all patients having 1þ or
less MR during predischarge examination, and all but 3 pa-
tients having 1þor less MR during 6 months follow-up. No
patient had more than 2þMR at any time during the study
period.
The DYANA mitral annuloplasty device allows for ad-
justments to the ring size and shape under physiologic con-
ditions, that is, when the heart is fully loaded and separated
from CPB. In addition, changes in ring size can be achieved
in a matter of seconds and do not require any additional
CPB or myocardial ischemic time, in contrast with conven-
tional surgical techniques. Removal of the activation wires
through the closed left atrial incision was performed before
chest closure and was uneventful in all patients in the cur-
rent study, regardless if surgical access was performed via
a standard median sternotomy or minimally invasively. Fu-
ture device advancements will focus on the development of
a subcutaneous activation wire system, which could be ac-
tivated any time during patient follow-up. The second gen-
eration of the current device will allow postrepair activation
up to 6 months postoperatively and is currently being inves-
tigated in a multicenter study. Such a device may be partic-
ularly helpful in patients with functional MR, because
recurrent MR is known to occur months to years
postsurgery in a significant proportion of such patients.7-9
Previous in vitro and in vivo studies have demonstrated
that activation with maximal power will result in an in-
crease of the device surface temperature of 1C to 2C,
even at low-flow conditions. Chronic animal studies re-
vealed that the radiofrequency activation does not cause
damage, such as thermal injury or necrosis, to surrounding
tissue or blood cells. In addition, significant hemolysis
was not encountered in the present investigation. Ourery c February 2013
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pected range for this patient population undergoing MV
repair.28,29
We can therefore conclude that the implantation of
a novel dynamic, radiofrequency-activated annuloplasty
device allows for safe MV repair, with or without device ac-
tivation. Annuloplasty device activation is associated with
an improvement in MR grade in patients with intraoperative
residual MR. Further investigations will be required to de-
termine whether such intraoperative activations lead to im-
proved medium- and long-term durability of MV surgery,
particularly for patients with functional MR.Study Limitations
The main limitation of the current study was the lack of
a control group. However, the trial was designed as first-
in-human, multicenter, prospective study to assess device
safety. Despite the fact that device safety was the primary
outcome, we were able to demonstrate device efficacy in
a small number of patients with residual MR. Unfortu-
nately, there was a significant number of absent patients at
the 30-day follow-up visit; however, the late follow-up
was 97% complete.
All modifications of septal-lateral diameter by activation
of the nitinol-based ring in this study were made in patients
receiving D rings if residual MR was encountered during
postrepair TEE. Because none of the patients presented
with SAM, none of the Dþ rings had been activated. Thus,
we can only speculate on salutary effects of increasing the
septal-lateral diameter for treatment of SAM.
The authors thank Drs Ottavio Alfieri and Maurice Buchbinder
for contributions in the design and development of the novel dy-
namic annuloplasty device.References
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